Progesterone Receptor Negative Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

DBCOND0038639 (Progesterone Receptor Negative)Recruiting2 IdentifierTitlePurposeDrugs
NCT02648477Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerTreatment
NCT02957968Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaTreatment
NCT02411656Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyTreatment